- As per Spherical Insights & Consulting, The Global Glomerulonephritis Market Size is expected to Grow from USD 11.63 Billion in 2024 to USD 18.63 Billion by 2035, at a CAGR of 4.38% during the forecast period 2025-2035, owing to the launch of new therapies in the market and the rise in the number of cases.
- The leading Glomerulonephritis Market Companies such as AstraZeneca, Amgen, Teva Pharmaceuticals, Astellas Pharma, Roche, Sanofi, Otsuka Holdings, Bayer, Pfizer, Merck & Co., Bristol-Myers Squibb, Novartis, AbbVie, Boehringer Ingelheim, GlaxoSmithKline, and Others.

Glomerulonephritis Treatment Market: Understanding and Treatment Algorithm:
Glomerulonephritis is an inflammation of the glomeruli, the tiny filtering units in the kidneys. It can be acute or chronic and results from infections, autoimmune diseases, or other causes. This condition impairs kidney function, leading to symptoms like blood in urine, swelling, and potential kidney failure if untreated.
Glomerulonephritis Diagnosis:
Diagnosis involves urine and blood tests to detect proteinuria, hematuria, and kidney function markers. Imaging tests like ultrasound assess kidney size and structure. A kidney biopsy is often performed to confirm the type and severity of glomerulonephritis, guiding treatment decisions and prognosis.
Glomerulonephritis Treatment:
Treatment depends on the underlying cause and severity. It may include corticosteroids, immunosuppressants, blood pressure control, and supportive care like dialysis. Newer therapies target specific immune pathways to reduce inflammation and prevent progression, aiming to preserve kidney function and improve patient outcomes.
Glomerulonephritis Epidemiology:
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glomerulonephritis, Gender specific Diagnosed Incidence of Glomerulonephritis, Type specific Diagnosed Incidence of Glomerulonephritis, Age specific Diagnosed Incidence of Glomerulonephritis, Diagnosed Incident Population based on Primary Site of Glomerulonephritis, and Diagnosed Incident Population based on Histologic Classification of Glomerulonephritis Tumour in the global market covering North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa from 2024 to 2035.
Principal Insights:
This section offers a global overview of glomerulonephritis epidemiology in major markets worldwide.
Country Wise Glomerulonephritis Multiforme Epidemiology:
- The epidemiology segment provides Glomerulonephritis prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia-Pacific (including Japan), Latin America, the Middle East, and Africa.
Glomerulonephritis: Recent Developments:
- In February 2023, Travere Therapeutics announced that the U.S. FDA granted accelerated approval for FILSPARI (sparsentan), marking it as the first and only non-immunosuppressive therapy approved for reducing proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. The approval was based on interim data from a pivotal clinical trial.
Glomerulonephritis Marketed Drugs:
• FILSPARI: Travere Therapeutics
FILSPARI (sparsentan) is a dual endothelin angiotensin receptor antagonist. It is FDA-approved under accelerated approval for the reduction of proteinuria in adults with primary IgA nephropathy. It is the first and only non-immunosuppressive therapy in this indication and is used in patients at risk of disease progression.
• TARPEYO: Calliditas Therapeutics
TARPEYO (budesonide) is a targeted-release corticosteroid designed to act on mucosal B cells in the ileum. It received FDA accelerated approval for the treatment of IgA nephropathy, where it helps reduce proteinuria in adults. It is specifically formulated to deliver therapy directly to sites associated with disease activation.
Glomerulonephritis: Emerging Therapies:
- Atacicept: It is a fusion protein in late-stage trials for IgA nephropathy. It targets BLyS and APRIL cytokines to reduce B-cell activity and antibody production, aiming to lower proteinuria and preserve kidney function in patients with immune-mediated glomerulonephritis.
- Iptacopan: It is an oral complement factor B inhibitor in advanced development for C3 glomerulopathy and IgA nephropathy. It blocks the alternative complement pathway to prevent kidney inflammation and damage, offering a novel treatment for patients resistant to current therapies.
Glomerulonephritis Market Outlook:
- The glomerulonephritis market encompasses therapies, diagnostics, and supportive care targeting inflammation of the glomeruli in the kidneys. It includes treatment for various types, like acute, chronic, and autoimmune-related, aiming to prevent kidney failure and manage symptoms effectively.
- Rising prevalence of chronic kidney diseases, increased diagnosis rates through advanced testing, growing geriatric population, and advancements in targeted therapies drive market growth. Additionally, heightened awareness and increasing healthcare expenditure fuel demand for better glomerulonephritis management worldwide.
- Emerging novel therapies like complement inhibitors, growing investments in R&D, and expanding healthcare infrastructure in developing regions offer significant opportunities. Increasing early diagnosis through non-invasive tests and rising patient access to treatment also present avenues for market expansion.
- Governments worldwide are supporting chronic kidney disease management through funding, awareness campaigns, and improved diagnostic guidelines. Policies promoting early detection, patient education, and reimbursement for innovative therapies contribute to better glomerulonephritis outcomes and market growth.
- High treatment costs and limited access to advanced therapies in low-income regions restrain market growth.
- The market is projected to grow robustly due to increasing disease prevalence and ongoing development of innovative, targeted therapies improving patient outcomes.
Glomerulonephritis Market Segmentation:
By Type:
- Acute Glomerulonephritis
- Chronic Glomerulonephritis
- Others

Chronic Glomerulonephritis holds the largest market share due to its progressive nature and long-term treatment needs. Unlike acute cases, chronic conditions require ongoing monitoring, dialysis, or kidney transplantation, driving consistent demand for therapeutic interventions and diagnostics. Its higher global prevalence also significantly contributes to market dominance.
By Diagnosis:
- Urine and Blood Test
- Imaging Tests
- Kidney Biopsy
- Others

Urine And Blood Tests dominate the diagnostic segment due to their non-invasive nature, cost-effectiveness, and routine use in early detection and monitoring of glomerulonephritis. These tests are widely accessible, quick to perform, and provide critical information on kidney function, making them the first-line diagnostic tools across healthcare settings.
Regional Segment Analysis of the Glomerulonephritis Market:
North America holds the largest share in the glomerulonephritis market, driven by its advanced healthcare infrastructure, high awareness levels, and widespread access to diagnostic and treatment options. The region benefits from robust research initiatives, favourable reimbursement policies, and a high prevalence of chronic kidney diseases. Additionally, the presence of leading pharmaceutical and biotech companies contributes to market dominance through the development of innovative therapeutic and diagnostic solutions.
The Asia-Pacific region is the fastest growing in the glomerulonephritis market due to rising healthcare expenditure, increasing patient population, and growing awareness of kidney disorders. Countries like China and India are experiencing rapid advancements in healthcare infrastructure and diagnostics. Government initiatives supporting chronic disease management and increasing investments by global healthcare companies are further accelerating growth. Moreover, improving access to healthcare services is boosting early detection and treatment in the region.
Glomerulonephritis Market Key Companies:
- AstraZeneca
- Amgen
- Teva Pharmaceuticals
- Astellas Pharma
- Roche
- Sanofi
- Otsuka Holdings
- Bayer
- Pfizer
- Merck & Co.
- Bristol-Myers Squibb
- Novartis
- AbbVie
- Boehringer Ingelheim
- GlaxoSmithKline
- Others
Glomerulonephritis Therapeutics Market Report Scope:
- The Glomerulonephritis therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
- Detailed insights into Glomerulonephritis’s epidemiology and therapeutic approaches are included.
- Additionally, a comprehensive review of existing and emerging Glomerulonephritis therapies is provided, including an evaluation of new treatments expected to influence the current Glomerulonephritis treatment market landscape.
- The report includes a detailed review of the Glomerulonephritis therapeutics market, both historical and forecasted, highlighting the global drug reach.
- The Patient-Based Glomerulonephritis Market Forecasting report offers valuable insights into trends shaping the global Glomerulonephritis market, helping to develop effective business strategies.
Glomerulonephritis Treatment Market Report Insights:
- Forecasting Market Trends Based on Patient Data and Disease Rates
- Glomerulonephritis Therapeutic Approaches in Glomerulonephritis
- Review Of Drugs in Development for Glomerulonephritis
- Market, Growth, and Trends in Glomerulonephritis
- Market Opportunities in Glomerulonephritis Treatment
- Effects Of Future Therapies on Glomerulonephritis Treatment.
Glomerulonephritis Treatment Market Report Key Strengths
- 15 Years Glomerulonephritis Market Forecast
- Global Coverage
- Glomerulonephritis Epidemiology Segmentation
- Key Cross Competition
Glomerulonephritis Treatment Market Report Assessment
- Present Practices in the Glomerulonephritis Treatment Market
- Review of Investigational Glomerulonephritis Drugs
- Attractiveness of the Glomerulonephritis Drug Market
- Glomerulonephritis Market Drivers
- Glomerulonephritis Market Barriers
- SWOT
- Attribute Analysis
Market Segment:
This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the glomerulonephritis market based on the following segments:
Global Glomerulonephritis Market, By Type
- Acute Glomerulonephritis
- Chronic Glomerulonephritis
- Others
Global Glomerulonephritis Market, By Diagnosis
- Urine and Blood Test
- Imaging Tests
- Kidney Biopsy
- Others
Global Glomerulonephritis Market, By Regional Analysis
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa